BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lai YC, Shih CY, Jeng CM, Yang SS, Hu JT, Sung YC, Liu HT, Hou SM, Wu CH, Chen TK. Hepatic arterial infusion chemotherapy for hepatocellular carcinoma with tumor thrombosis of the portal vein tumor thrombosis. World J Gastroenterol 2003; 9(12): 2666-2670 [PMID: 14669309 DOI: 10.3748/wjg.v9.i12.2666] [Cited by in CrossRef: 39] [Cited by in F6Publishing: 37] [Article Influence: 2.1] [Reference Citation Analysis]
Number Citing Articles
1 Ikeda M, Okusaka T, Furuse J, Mitsunaga S, Ueno H, Yamaura H, Inaba Y, Takeuchi Y, Satake M, Arai Y. A multi-institutional phase II trial of hepatic arterial infusion chemotherapy with cisplatin for advanced hepatocellular carcinoma with portal vein tumor thrombosis. Cancer Chemother Pharmacol. 2013;72:463-470. [PMID: 23812005 DOI: 10.1007/s00280-013-2222-x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 2.6] [Reference Citation Analysis]
2 Yamashita T. Current status of hepatocellular carcinoma treatment in Japan: hepatic arterial infusion chemotherapy. Clin Drug Investig 2012;32 Suppl 2:15-23. [PMID: 22873624 DOI: 10.1007/BF03265493] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
3 Lin CC, Hung CF, Chen WT, Lin SM. Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma with Portal Vein Thrombosis: Impact of Early Response to 4 Weeks of Treatment. Liver Cancer 2015;4:228-40. [PMID: 26734578 DOI: 10.1159/000367737] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
4 Ishii S, Sato M, Sonomura T, Yamada K, Tanihata H, Ishikawa H, Terada M, Sahara S, Kawai N, Kimura M, Mori I. Optimal Covering Material for Stent-Grafts Placed in the Portal Vein in a Canine Model. Cardiovasc Intervent Radiol 2005;28:624-31. [DOI: 10.1007/s00270-004-0221-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
5 Zhou L, Rui J, Wang S, Chen S, Qu Q. Clinicopathological Predictors of Poor Survival and Recurrence After Curative Resection in Hepatocellular Carcinoma Without Portal Vein Tumor Thrombosis. Pathol Oncol Res 2015;21:131-8. [DOI: 10.1007/s12253-014-9798-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
6 Georgiades CS, Hong K, D’Angelo M, Geschwind JF. Safety and efficacy of transarterial chemoembolization in patients with unresectable hepatocellular carcinoma and portal vein thrombosis. J Vasc Interv Radiol. 2005;16:1653-1659. [PMID: 16371532 DOI: 10.1097/01.rvi.0000182185.47500.7a] [Cited by in Crossref: 152] [Cited by in F6Publishing: 59] [Article Influence: 9.5] [Reference Citation Analysis]
7 Sano S, Nakata S, Wada S, Kuroiwa M, Sakai H, Kusama K, Machida T, Nishio A, Ito I, Sodeyama H. Pathological complete response by advanced hepatocellular carcinoma with massive macrovascular invasion to hepatic arterial infusion chemotherapy: a case report. World J Surg Oncol 2019;17:229. [PMID: 31878937 DOI: 10.1186/s12957-019-1772-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
8 Katamura Y, Aikata H, Takaki S, Azakami T, Kawaoka T, Waki K, Hiramatsu A, Kawakami Y, Takahashi S, Kenjo M, Toyota N, Ito K, Chayama K. Intra-arterial 5-fluorouracil/interferon combination therapy for advanced hepatocellular carcinoma with or without three-dimensional conformal radiotherapy for portal vein tumor thrombosis. J Gastroenterol. 2009;44:492-502. [PMID: 19330281 DOI: 10.1007/s00535-009-0033-y] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 3.2] [Reference Citation Analysis]
9 Ueshima K, Kudo M, Tanaka M, Kumada T, Chung H, Hagiwara S, Inoue T, Yada N, Kitai S. Phase I/II Study of Sorafenib in Combination with Hepatic Arterial Infusion Chemotherapy Using Low-Dose Cisplatin and 5-Fluorouracil. Liver Cancer 2015;4:263-73. [PMID: 26734580 DOI: 10.1159/000367751] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
10 Yang M, Fang Z, Yan Z, Luo J, Liu L, Zhang W, Wu L, Ma J, Yang Q, Liu Q. Transarterial chemoembolisation (TACE) combined with endovascular implantation of an iodine-125 seed strand for the treatment of hepatocellular carcinoma with portal vein tumour thrombosis versus TACE alone: a two-arm, randomised clinical trial. J Cancer Res Clin Oncol. 2014;140:211-219. [PMID: 24374800 DOI: 10.1007/s00432-013-1568-0] [Cited by in Crossref: 33] [Cited by in F6Publishing: 40] [Article Influence: 3.7] [Reference Citation Analysis]
11 Song DS, Bae SH, Song MJ, Lee SW, Kim HY, Lee YJ, Oh JS, Chun HJ, Lee HG, Choi JY, Yoon SK. Hepatic arterial infusion chemotherapy in hepatocellular carcinoma with portal vein tumor thrombosis. World J Gastroenterol 2013; 19(29): 4679-4688 [PMID: 23922465 DOI: 10.3748/wjg.v19.i29.4679] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
12 Damdinsuren B, Nagano H, Monden M. Combined intra-arterial 5-fluorouracil and subcutaneous interferon-alpha therapy for highly advanced hepatocellular carcinoma. Hepatol Res 2007;37 Suppl 2:S238-50. [PMID: 17877489 DOI: 10.1111/j.1872-034X.2007.00191.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
13 Kimura O, Kondo Y, Shimosegawa T. PPAR Could Contribute to the Pathogenesis of Hepatocellular Carcinoma. PPAR Res. 2012;2012:574180. [PMID: 23316217 DOI: 10.1155/2012/574180] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
14 Huang MJ, Yang SS, Lin MS, Huang CS. Polymorphisms of uridine-diphosphoglucuronosyltransferase 1A7 gene in Taiwan Chinese. World J Gastroenterol 2005; 11(6): 797-802 [PMID: 15682470 DOI: 10.3748/wjg.v11.i6.797] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.1] [Reference Citation Analysis]
15 Uka K, Aikata H, Takaki S, Miki D, Kawaoka T, Jeong SC, Takahashi S, Toyota N, Ito K, Chayama K. Pretreatment predictor of response, time to progression, and survival to intraarterial 5-fluorouracil/interferon combination therapy in patients with advanced hepatocellular carcinoma. J Gastroenterol. 2007;42:845-853. [PMID: 17940838 DOI: 10.1007/s00535-007-2099-8] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 2.7] [Reference Citation Analysis]
16 Shao Y, Liang P, Wu Y, Huang C, Huang K, Cheng JC, Hsu C, Hsu C, Cheng A, Lin Z. A pilot study of hepatic arterial infusion of chemotherapy for patients with advanced hepatocellular carcinoma who have failed anti-angiogenic therapy. Liver Int 2013;33:1413-9. [DOI: 10.1111/liv.12207] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
17 Eun JR, Lee HJ, Moon HJ, Kim TN, Kim JW, Chang JC. Hepatic arterial infusion chemotherapy using high-dose 5-fluorouracil and cisplatin with or without interferon-α for the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombosis. Scandinavian Journal of Gastroenterology 2009;44:1477-86. [DOI: 10.3109/00365520903367262] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 1.4] [Reference Citation Analysis]
18 Pleguezuelo M, Germani G, Marelli L, Xiruochakis E, Misseri M, Manousou P, Arvaniti V, Burroughs AK. Evidence-based diagnosis and locoregional therapy for hepatocellular carcinoma. Expert Review of Gastroenterology & Hepatology 2014;2:761-84. [DOI: 10.1586/17474124.2.6.761] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
19 Schillaci O, Filippi L, Danieli R, Simonetti G. Single-Photon Emission Computed Tomography/Computed Tomography in Abdominal Diseases. Seminars in Nuclear Medicine 2007;37:48-61. [DOI: 10.1053/j.semnuclmed.2006.07.001] [Cited by in Crossref: 39] [Cited by in F6Publishing: 23] [Article Influence: 2.6] [Reference Citation Analysis]
20 Ruan DT, Warren RS. Palliative techniques for hepatic cancer. Surg Oncol Clin N Am 2004;13:505-16, ix. [PMID: 15236732 DOI: 10.1016/j.soc.2004.04.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
21 Gao S, Zhang PJ, Guo JH, Chen H, Xu HF, Liu P, Yang RJ, Zhu X. Chemoembolization alone vs combined chemoembolization and hepatic arterial infusion chemotherapy in inoperable hepatocellular carcinoma patients. World J Gastroenterol 2015; 21(36): 10443-10452 [PMID: 26420971 DOI: 10.3748/wjg.v21.i36.10443] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
22 Tajiri K, Kawai K, Minemura M, Yasumura S, Hosokawa A, Kawabe H, Tomizawa G, Sugiyama T. Neutrophil/lymphocyte ratio as a prognostic indicator of hepatic arterial infusion chemotherapy with arterial cisplatin plus continuous 5-fluorouracil. Hepatol Res 2015;45:755-63. [PMID: 25196816 DOI: 10.1111/hepr.12417] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
23 Zhao L, Mou DC, Leng XS, Peng JR, Wang WX, Huang L, Li S, Zhu JY. Expression of cancer-testis antigens in hepatocellular carcinoma. World J Gastroenterol 2004; 10(14): 2034-2038 [PMID: 15237429 DOI: 10.3748/wjg.v10.i14.2034] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 19] [Article Influence: 1.3] [Reference Citation Analysis]
24 Nishikawa H, Osaki Y, Kita R, Kimura T. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma in Japan. Cancers (Basel) 2012;4:165-83. [PMID: 24213234 DOI: 10.3390/cancers4010165] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
25 Mikami E, Kanno N, Ueno Y, Shimosegawa T. Retrospective evaluation of tumor-mass-reduction therapy for the prognosis of recurrent hepatocellular carcinoma. Hepatol Int 2007;1:460-8. [PMID: 19669343 DOI: 10.1007/s12072-007-9021-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
26 Moriguchi M, Aramaki T, Nishiofuku H, Sato R, Asakura K, Yamaguchi K, Tanaka T, Endo M, Itoh Y. Sorafenib versus Hepatic Arterial Infusion Chemotherapy as Initial Treatment for Hepatocellular Carcinoma with Advanced Portal Vein Tumor Thrombosis. Liver Cancer 2017;6:275-86. [PMID: 29234631 DOI: 10.1159/000473887] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
27 Zhang ZH, Liu QX, Zhang W, Ma JQ, Wang JH, Luo JJ, Liu LX, Yan ZP. Combined endovascular brachytherapy, sorafenib, and transarterial chemobolization therapy for hepatocellular carcinoma patients with portal vein tumor thrombus. World J Gastroenterol 2017; 23(43): 7735-7745 [PMID: 29209114 DOI: 10.3748/wjg.v23.i43.7735] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
28 Peng ZH, Yang JM, Tang B, Si SH, Fang DC, Luo YH. Effects of metastasis-suppressor gene KAI1 on tumorigenicity and metastasis of hepatocellular carcinoma MHCC97-H cells with high metastatic potential in nude mice. Shijie Huaren Xiaohua Zazhi 2004; 12(4): 778-781 [DOI: 10.11569/wcjd.v12.i4.778] [Reference Citation Analysis]
29 Peng BG, He Q, Li JP, Zhou F. Adjuvant transcatheter arterial chemoembolization improves efficacy of hepatectomy for patients with hepatocellular carcinoma and portal vein tumor thrombus. Am J Surg. 2009;198:313-318. [PMID: 19285298 DOI: 10.1016/j.amjsurg.2008.09.026] [Cited by in Crossref: 87] [Cited by in F6Publishing: 96] [Article Influence: 6.7] [Reference Citation Analysis]
30 Kim SH, Oh JS, Chun HJ, Choi BG, Lee HG. Dual-Port versus Mono-Port Implantation for Intra-Arterial Chemoinfusion Therapy for Treatment of Hepatocellular Carcinoma in Patients with Anatomic Hepatic Artery Variation. J Vasc Interv Radiol. 2019;30:23-30. [PMID: 30297310 DOI: 10.1016/j.jvir.2018.06.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
31 Lu Y, Wu L, Lü Z, Wang X, Yang J. Expression of SSX-1 and NY-ESO-1 mRNA in tumor tissues and its corresponding peripheral blood expression in patients with hepatocellular carcinoma: . Chinese Medical Journal 2007;120:1042-6. [DOI: 10.1097/00029330-200706020-00003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
32 Niizeki T, Sumie S, Torimura T, Kurogi J, Kuromatsu R, Iwamoto H, Aino H, Nakano M, Kawaguchi A, Kakuma T, Sata M. Serum vascular endothelial growth factor as a predictor of response and survival in patients with advanced hepatocellular carcinoma undergoing hepatic arterial infusion chemotherapy. J Gastroenterol 2012;47:686-95. [DOI: 10.1007/s00535-012-0555-6] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 3.3] [Reference Citation Analysis]
33 Lubienski A, Simon M, Lubienski K, Gellissen J, Hoffmann R, Jakobs T, Helmberger T. Update Chemoperfusion und -embolisation. Radiologe 2007;47:1097-108. [DOI: 10.1007/s00117-007-1587-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
34 Uka K, Aikata H, Takaki S, Kawaoka T, Saneto H, Miki D, Takahashi S, Toyota N, Ito K, Chayama K. Systemic gemcitabine combined with intra-arterial low-dose cisplatin and 5-fluorouracil for advanced hepatocellular carcinoma: Seven cases. World J Gastroenterol 2008; 14(16): 2602-2608 [PMID: 18442216 DOI: 10.3748/wjg.14.2602] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
35 Katamura Y, Aikata H, Kimura Y, Azakami T, Kawaoka T, Takaki S, Waki K, Hiramatsu A, Kawakami Y, Takahashi S, Chayama K. Successful treatment of pulmonary metastases associated with advanced hepatocellular carcinoma by systemic 5-fluorouracil combined with interferon-α in a hemodialysis patient. Hepatology Research 2009;39:415-20. [DOI: 10.1111/j.1872-034x.2008.00448.x] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
36 Yoon I, Yim HJ, Kim JN, Park SM, Kim JH, Lee SH, Chung HH, Lee HS, Lee SW, Choi JH. [A case of advanced hepatocellular carcinoma with portal vein tumor invasion controlled by percutaneous ethanol injection therapy]. Korean J Hepatol 2009;15:90-5. [PMID: 19346790 DOI: 10.3350/kjhep.2009.15.1.90] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
37 Song DS, Song MJ, Bae SH, Chung WJ, Jang JY, Kim YS, Lee SH, Park JY, Yim HJ, Cho SB, Park SY, Yang JM. A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis. J Gastroenterol. 2015;50:445-454. [PMID: 25027973 DOI: 10.1007/s00535-014-0978-3] [Cited by in Crossref: 63] [Cited by in F6Publishing: 66] [Article Influence: 7.9] [Reference Citation Analysis]
38 Shao YY, Huang CC, Liang PC, Lin ZZ. Hepatic arterial infusion of chemotherapy for advanced hepatocellular carcinoma. Asia Pac J Clin Oncol 2010;6:80-8. [PMID: 20565419 DOI: 10.1111/j.1743-7563.2010.01287.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]